LDRT Combined With Pucotenlimab and Standard Therapy for Advanced Pancreatic Cancer: A Single-Arm Study
Recruiting now · Phase 1/Phase 2
Conditions studied: Pancreatic Cancer, PD-L1, PD-1 Inhibitor, LDRT, Proterizumab
In brief
To investigate the activating effect of local lesion low-dose radiotherapy (2Gy) on the tumor immune microenvironment, and the efficacy, safety, and feasibility of its combination with pembrolizumab and standard therapy in patients with advanced pancreatic cancer. Concurrently, to preliminarily establish an efficacy prediction model for the early identification of patient populations who would benefit from the treatment, thereby providing a theoretical foundation for the implementation of precision medicine.
Key facts
- Study ID
- NCT07312422
- Run by
- Zhejiang Provincial People's Hospital
- People needed
- 10
- Starts
- 2025-09-30
- Expected to finish
- 2026-10-30
- Last updated by the study team
- 2026-01-26
Who can join
Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Age ≥ 18 years, regardless of gender;
- ECOG score of 0 to 1;
- Patients with histologically or cytologically confirmed pancreatic malignancy;
- No prior treatment with PD-1 or PD-L1 inhibitors;
- Presence of a radiotherapeutically eligible target lesion (excluding bone metastases);
- Subjects voluntarily participate in the study and provide signed informed consent.
You may not qualify if…
- Previous history of radiotherapy;
- Uncontrolled chronic infectious or non-infectious diseases, including but not limited to: medication-refractory heart failure, poorly controlled hypertension, etc.;
- Active or clinically uncontrolled severe infections;
- History of psychoactive drug abuse that cannot be abstained from, or patients with psychiatric disorders;
- Pregnant or lactating women, or patients of childbearing potential who are unwilling or unable to adopt effective contraceptive measures;
- Other conditions deemed by the investigator as potentially affecting the conduct of the clinical study or the interpretation of study results.
Where it is running
- Zhejiang Provincial People's Hospital — Hangzhou, Zhejiang, China (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.